Loading stock data…
VERA
$35.20-0.41 (-1.15%)
Market ClosedLast close May 1
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Vera Therapeutics, Inc. in the Healthcare sector is trading at $35.20. The stock is currently 37% below its 52-week high of $56.05, remaining 0.5% above its 200-day moving average. Technical signals show oversold RSI of 9 and bearish MACD signal, explaining why VERA maintains its current momentum and trend strength. The Whystock Score of 70/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Oversold momentum (RSI 9) — potential for technical mean-reversion
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$35.20
Potential Upside
5%
Whystock Fair Value$36.96
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus14 analysts
Mean target$79.00+124.4%
Range$35.00 – $110.00
Fundamentals
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion pr...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.75B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.17
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-36.11%
Volume
Today's trading volume
823,716
Recent News
Is Vera Therapeutics (VERA) Still Attractive After An 87% One Year Share Price Surge
If you are wondering whether Vera Therapeutics at around US$40.93 is still offering value or if the best days are already priced in, this breakdown is for you. The stock has returned 0.2% over the last 7 days, 1.7% over the last month, a 15.8% decline year to date, and 87.7% over the last year, with a very large 3 year return that is well above 7x. Recent coverage around Vera Therapeutics has focused on its position within the biotech space and how investors are assessing future prospects...
These 5 Biotechs Could Be the Next Big GLP-1 Acquisition Target
The GLP-1 revolution has reshaped biopharma M&A strategy. With Novo Nordisk and Eli Lilly generating tens of billions in annual obesity drug revenue, large-cap acquirers are scouring the biotech landscape for the next transformative asset. The following five companies represent compelling acquisition targets, ranging from pure-play GLP-1 developers to adjacent pipeline builders that could diversify ... These 5 Biotechs Could Be the Next Big GLP-1 Acquisition Target
High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding
This biotechnology firm develops precision therapies for rare, genetically defined diseases, with a focus on targeted cancer treatments.
This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know
This clinical-stage biotech develops antibody therapies for thyroid eye disease, advancing multiple candidates through its R&D pipeline.
This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know
This clinical-stage biotech develops bladder-sparing therapies for high-risk cancer patients, targeting unmet needs in oncology treatment.